Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors
NCT03693846Phase 2Terminated
- Sponsor
- Abramson Cancer Center
- Start
- Feb 2019
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and ipilimumab in colorectal cancer (CRC) and appendiceal cancer, sponsored by Abramson Cancer Center. Primary endpoint: Progression-Free Survival at 6 Months. Started Feb 2019; status: terminated.
02
Drugs
nivolumabipilimumab
03
Conditions
colorectal cancer (CRC)appendiceal cancer
Beyond the preview
Go deeper on NCT03693846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03693846.